A new publication involving cosyntropin was released on August 14, 2026. The study, titled "Liver cirrhosis is associated with altered glucocorticoid metabolism related to disease severity," appeared in the Journal of Internal Medicine.
The publication is listed under PubMed ID 42598738. It presents research connecting liver cirrhosis to changes in glucocorticoid metabolism, with the title indicating a relationship to disease severity.
No findings, results, or conclusions from the study have been detailed here beyond the title and publication information provided. The event data does not include specific outcomes, effect sizes, or clinical recommendations.
Cosyntropin is an approved compound, and this publication represents a new addition to the scientific literature referencing it. Readers interested in the full scope of the study's methodology and results should consult the original source directly through the Journal of Internal Medicine.
For more background on cosyntropin, including its approved uses and general profile, readers can refer to the compound overview.